What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “XTR004 as the experiemental drug, 99mTechnetium Sestamibi as the Active Comparator, and Coronary artery angiography as the refenrece standard”In the company’s words, NCT07439133 on ClinicalTrials.gov
- Tested for
- Coronary Artery Disease(CAD)
- Main trialPhase 3
- “The primary objective of this study is to evaluate the effectiveness of visual reading in XTR004 PET myocardial perfusion imaging (MPI) for detecting restrictive stenosis, using quantitative coronary angiography (QCA) and fractional flow reserve (FFR) as reference standards in patients with suspected or known coronary artery disease.”In the company’s words, NCT07439133 on ClinicalTrials.gov
Other drugs for Coronary Artery Disease(CAD)
- EA-230EBI Anti Sepsis BV · Phase 3
- ObicetrapibNewAmsterdam Pharma · Phase 3
- Bempedoic acid/ezetimibeDaiichi Sankyo · Phase 3
- ZiltivekimabNovo Nordisk · Phase 3
- RetatrutideEli Lilly · Phase 3
- InclisiranNovartis · Phase 3
Coming up1
- Jun 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2027 | Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | |
| Phase 2Completed | 9 May 2023 | Evaluation of XTR004 as a Novel 18F-labeled PET MPI Tracer in Diagnosis of Known or Suspected CAD | |
| Phase 2Terminated | 5 Mar 2025 | Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026